Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, 58th, The Second Zhongshan Road, Guangzhou, Guangdong 510080, China.
Faculty of Medicine and Dentistry, University of Western Australia, Perth, WA, Australia.
Contrast Media Mol Imaging. 2017 Jul 10;2017:7350429. doi: 10.1155/2017/7350429. eCollection 2017.
To investigate the effectiveness of a new individualized contrast medium injection protocol for enhanced liver CT scan.
324 patients who underwent plain and dual phase enhanced liver CT were randomly assigned to 2 groups: G1 ( = 224, individualized contrast medium injection protocol); G2 ( = 100, standard contrast medium injection with a dose of 1.5 ml/kg). CT values and ΔHU (CT values difference between plain and enhanced CT) of liver parenchyma and tumor-liver contrast (TLC) during hepatic arterial phase (HAP) and portal venous phase (PVP) and contrast medium dose were measured. The tumor conspicuity of hepatocellular carcinoma (HCC) between two groups was independently evaluated by two radiologists.
The mean contrast medium dose of G1 was statistically lower than that of G2. There were no significantly statistical differences in CT values and ΔHU of liver parenchyma during HAP, TLC values during HAP, and PVP between two groups. The CT values and ΔHU of liver parenchyma during PVP of G2 were significantly higher than those of G1. Two independent radiologists were both in substantial conformity in grading tumor conspicuity.
Using the individually optimized injection protocol might reduce contrast medium dose without impacting on the imaging quality in enhanced liver CT.
探讨一种新的个体化对比剂注射方案在增强 CT 肝脏扫描中的有效性。
将 324 例行平扫及双期增强 CT 肝脏检查的患者随机分为 2 组:G1 组(n = 224,个体化对比剂注射方案);G2 组(n = 100,标准对比剂注射方案,剂量为 1.5ml/kg)。测量肝脏实质的 CT 值和 ΔHU(平扫和增强 CT 值的差值),以及肝动脉期(HAP)和门静脉期(PVP)的肿瘤肝对比(TLC),并测量对比剂用量。由 2 位放射科医生独立评估两组肝细胞癌(HCC)的肿瘤显影。
G1 组的平均对比剂剂量明显低于 G2 组。两组间 HAP 期肝脏实质 CT 值和 ΔHU、HAP 期 TLC 值、PVP 期肝脏实质 CT 值和 ΔHU 均无显著统计学差异。G2 组 PVP 期肝脏实质 CT 值和 ΔHU 明显高于 G1 组。2 位独立的放射科医生在评估肿瘤显影的分级方面均具有高度一致性。
使用个体化优化的注射方案可以在不影响增强 CT 肝脏成像质量的情况下降低对比剂剂量。